Quarterly report pursuant to Section 13 or 15(d)

Corporate Information - Narrative (Details)

v3.22.1
Corporate Information - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
May 31, 2013
Business Acquisition [Line Items]        
Cash, cash equivalents and investments $ 100,300      
Net loss (5,101) $ (4,172)    
Accumulated deficit $ (262,245)   $ (257,144)  
Pieris Pharmaceuticals GmbH        
Business Acquisition [Line Items]        
Ownership interest acquired (as a percent)       100.00%